type here...

The Equitable Economy

Antitrust and Competition

Novo Nordisk’s Offer To Acquire Metsera Constitutes Attempted Monopolization

Hannah Pittock
Hannah Pittock uses weight-loss company Novo Nordisk’s offer to acquire Metsera to create a three-prong framework by which the antitrust agencies can identify when an invitation to exclude a rival from a market constitutes illegal exclusionary conduct under Section 2 of the Sherman Act.
Commentary

Why the Controversy Behind ExxonMobil’s New Retail Voting Program?

Andy Shi
ProMarket Managing Editor Andy Shi reviews the controversy behind ExxonMobil’s new voting program and how it falls into the broader debates over recent developments to shareholder democracy and corporate governance.
Commentary

The Economics of Zohran Mamdani

Nikolaos Chatzarakis
Nikolaos Chatzarakis reviews some of the key economic platforms of New York City Mayor-elect Zohran Mamdani. He argues that Mamdani’s platform is ambitious but not unrealistic, and that criticisms of it often rely on simplistic models and theory. Still, there remain areas for improvement.
Antitrust and Competition

Novo Nordisk’s Killer Non-Acquisition Merger Contract Proposal Is a Case of “Heads I Win, Tails You Lose”

Steven Salop
Steve Salop explores the anticompetitive innovation behind weight-loss giant Novo Nordisk’s offer to acquire Metsera. Novo’s proposed contract presents a new tactic by which firms with market power can preclude rival mergers that will lead to procompetitive entry.
Commentary

How the Law Protects and Promotes Corporate Misconduct

Jennifer Taub
Corporate crimes like fraud continue unabated in the United States. Jennifer Taub defines a chief reason as “accountability theater,” or the propensity of government prosecutors to pursue out-of-court civil settlements rather than criminal trials that, though they might lose them, would publicize the extent of corporate misconduct and better deter future abuse.
Commentary

Will Trump’s Drug-Pricing Order Reduce Prices for Americans?

Margherita Colangelo
President Donald Trump has, across two administrations, sought to lower drug prices for Americans, most recently with executive order “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” Margherita Colangelo explains why his order is unlikely to accomplish its goal.
Book Reviews

How Income Inequality Today Differs From the Past

Surya Gowda
Surya Gowda reviews Branko Milanović’s Visions of Inequality: From the French Revolution to the End of the Cold War and how his analysis of class and inequality applies to contemporary America.
Labor

Accounting for City Size, Minimum Wages Reduce Jobs Almost Everywhere

Priyaranjan Jha
In new research, Priyaranjan Jha, Jyotsana Kala, David Neumark, and Antonio Rodriguez-Lopez find that studies arguing higher minimum wages have no employment effect—or even a positive effect—in many labor markets fail to account for how much less minimum wages matter in larger, higher-wage cities.
ESG, Corporate Governance & Future of the Firm

ESG Raters That Also Provide Index Funds May Skew Ratings

Suhas A. Sridharan
Some have argued that environmental, social, and governance (ESG) ratings are generally more reliable than credit ratings due to how the raters are paid for their work. In new research, Suhas Sridharan and coauthors find that significant conflicts of interest can arise for ESG raters when they also provide ESG index funds to investors.
Commentary

A Decentralized Education System Risks Slowing the Adoption of GenAI to the Harm of Students

Eli Orbach
Eli Orbach examines how the United States’s decentralized education system impedes the diffusion and adoption of generative artificial intelligence in K-12 schools. Slow and uneven diffusion will exacerbate current socioeconomic inequalities, harm students’ future work prospects, and impede macroeconomic growth and productivity.
123...45Page 1 of 45

Latest news

View All

The publication of the Stigler Center at The University of Chicago Booth School of Business

ProMarket is dedicated to discussing how competition tends to be subverted by special interests. The posts represent the opinions of their writers, not necessarily those of the University of Chicago, the Booth School of Business, or its faculty. For more information, please visit ProMarket Policy.